Last Updated: May 2026
Pancragen is a synthetic tetrapeptide (Lys-Glu-Asp-Trp) from the Khavinson bioregulator family, researched for pancreatic-tissue-targeted bioregulation, glucose regulation, and pancreatic beta-cell function. It is one of the better-studied Khavinson compounds in terms of mechanistic research, with chromatin-interaction studies providing relatively direct molecular evidence for the proposed epigenetic mechanism. Pancragen is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.
Pancragen is a synthetic Lys-Glu-Asp-Trp tetrapeptide proposed to enter pancreatic cell nuclei and modulate gene expression in pathways related to insulin production, pancreatic beta-cell function, and glucose homeostasis. It is among the Khavinson compounds with relatively well-characterized mechanistic studies — chromatin immunoprecipitation work has demonstrated tetrapeptide binding to specific DNA promoter regions in pancreatic-cell models. Within the Khavinson framework, Pancragen complements Ovagen (hepatic) in metabolic-organ targeting. Evidence level: Preclinical (cell culture with chromatin interaction data, rodent metabolic models); Khavinson-group research; independent replication limited.
Preclinical studies have reported effects on pancreatic gene expression markers, insulin secretion parameters in beta-cell culture models, and glucose tolerance improvements in diabetic rodent models. Chromatin immunoprecipitation studies from the Khavinson group have provided some of the most direct molecular evidence for the bioregulator framework, showing Pancragen binding to specific DNA promoter regions. Russian clinical use has been reported in adjunctive diabetes care contexts. FDA-grade Phase 2/3 has not been conducted. Evidence level: Preclinical with mechanistic detail; Khavinson-group human research; FDA-grade Phase 2/3 not conducted.
Pancragen operates through the proposed Khavinson epigenetic mechanism on pancreatic gene expression; GLP-1-class compounds like semaglutide and tirzepatide work through defined GLP-1 receptor pathways with extensive Phase 3 clinical evidence in type 2 diabetes. They are not mechanistically comparable, and the evidence base for diabetes efficacy is vastly larger for GLP-1 agonists.
| Compound | Mechanism | Diabetes evidence base | FDA status |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Phase 3 (SUSTAIN program) | FDA-approved |
| Tirzepatide | Dual GLP-1/GIP agonist | Phase 3 (SURPASS program) | FDA-approved |
| Pancragen | Proposed epigenetic pancreatic modulation | Preclinical + Khavinson research | Not approved |
Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. The favorable safety profile is consistent across the Khavinson bioregulator class. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards. Evidence level: Preclinical safety; human long-term unestablished.
Pancragen is not approved by the FDA, EMA, or any major Western regulator as of May 2026. Regulatory context in FDA peptide regulation 2025–2026 timeline.
Pancragen's tetrapeptide structure (Lys-Glu-Asp-Trp) is shared in core composition with other Khavinson tetrapeptides — making mass spectrometry identity confirmation essential to verify the correct sequence and the tryptophan residue specifically. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.
Peptigrity purchases Pancragen vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. Methodology in how we calculate trust scores.
Pancragen is proposed to act on pancreatic tissue through epigenetic gene-expression modulation, with preclinical research focused on insulin secretion, beta-cell function, and glucose tolerance. Some of the more direct mechanistic evidence for the bioregulator framework comes from chromatin-interaction studies of Pancragen.
No. Pancragen is not approved for diabetes treatment anywhere in the world. FDA-approved diabetes peptides include semaglutide, tirzepatide, and other GLP-1-class compounds — all with substantially larger evidence bases than Pancragen. Anyone considering diabetes management should consult a licensed physician about evidence-based options.
Pancragen is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.
No active FDA approval pathway exists for Pancragen as of May 2026.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation (the tryptophan residue is structurally distinctive and verifiable). COA interpretation in red flags in peptide certificates of analysis.
No. Pancragen is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.
This section is for educational and informational purposes only and does not constitute medical advice. Pancragen is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.